Oral Zinc Supplement as Adjunctive Therapy for Erosive Oral Lichen Planus
NCT ID: NCT06042010
Last Updated: 2023-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
22 participants
INTERVENTIONAL
2023-01-05
2023-02-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Zinc is a potent antioxidant micronutrient that contributes to the proper functioning of the antioxidant defense system. In addition, this mineral protects cells against inflammation by oxidative stress, because it acts in the stabilization of cell membrane. It also maintains macrophage and neutrophil functions, natural killer cell activity, and complement activity.
Matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases and have the main function of proteolytic degradation of connective tissue matrix proteins. Zinc prevents (MMP-1) activation and inhibition of the T-cell accumulation in (OLP) through inhibiting of (MMP-9).
Aim of the study: To evaluate and compare the efficacy of adding oral zinc supplementation 50 mg to 0.1%Triamcinolone orabase (TA)versus 0.1%Triamcinolone orabase alone on the healing of erosive OLP.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Oral Zinc Supplementation as an Adjuvant to Topical Corticosteroid in Oral Lichen Planus Patients
NCT04278599
Micronutrients in Management of Symptomatic Oral Lichen Planus
NCT04765267
Adjunctive Oral Systemic Vitamin E Therapy on Salivary Nitric Oxide Level in Patients With Erosive Oral Lichen Planus
NCT05787925
Efficacy of Ginger Muco-bioadhesive Gel in Management of Oral Lichen Planus With Immunohistochemical Analysis
NCT05882864
Glutamine With Topical Corticosteroids for Lichen Planus Treatment
NCT04442633
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test group
Oral zinc supplement
patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
control group
triamcinolone acetonide Oral paste
patients will received 0.1%triamcinolone acetonide Oral paste twice daily alone for 6weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral zinc supplement
patients received oral Zinc picolinate 50mg for 6 weeks as single morning dose along with 0.1%
triamcinolone acetonide Oral paste
patients will received 0.1%triamcinolone acetonide Oral paste twice daily alone for 6weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant and lactating females.
* Any patient that has history of cancer, kidney, liver or other autoimmune disease will be excluded from this study.
* Patients showing dysplastic changes in their confirmatory biopsy specimen will be also excluded.
* Any patients presenting with extra oral lichen planus lesions will be excluded.
* Suspicious lesions of both lichenoid contact reaction and lichenoid drug reaction lesions will be excluded.
* Vitamin administration intake within the last 3 months
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hams Hamed Abdelrahman
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hams Hamed Abdelrahman
Assistant lecturer of DPH and Clinical statistician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexandria Faculty of Dentistry
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Oral medicine_0424-04\2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.